Image source: © 2025 Krish Capital Pty. Ltd.

Highlights

  • Five-year exclusive distribution agreement signed with ITL, covering 15 countries and approximately 353 IVF clinics.

  • Initial minimum order of AUD 325,000 to be triggered upon CE Mark approval, with staged payments and recurring revenue potential.

  • Advanced negotiations underway in New Zealand, Japan, and India for additional volume-based agreements expected to generate revenue in FY2026.

Memphasys Limited (ASX:MEM), a reproductive biotechnology company, has entered into a five-year exclusive commercial distribution agreement with International Technical Legacy (ITL) of Doha, Qatar. The deal covers distribution of Felix™, Memphasys’ male fertility sperm preparation system, across 15 countries in the Middle East and North Africa (MENA).

Agreement Terms

The agreement grants ITL exclusive rights to market and distribute Felix™ across the MENA region. An initial minimum order valued at AUD 325,000 will be activated following CE Mark approval, lodged in June 2025 and expected within 12 months. The order includes 10 Felix™ consoles provided free of charge to new clinics, with additional cartridges and consoles to be supplied as demand increases.

The initial order is binding for two years, with pricing and minimum order volumes to be renegotiated for the following three years. Payment will be structured with 50% due on acceptance of the purchase order and the remaining 50% upon collection, with invoices payable within 30 days. This staged approach provides both early revenue visibility and a pathway to recurring revenues under the company’s consumables-driven model.

Market Scope

ITL is a recognised supplier of IVF infrastructure and consumables across the Middle East, working with more than 350 clinics and providing over 95% of supplies to clinics in Qatar. The MENA region performs around 140,000 IVF cycles annually, positioning Felix™ with access to a significant potential market.

In addition to distribution, ITL will actively promote Felix™, train clinicians, manage importation and logistics, and deliver after-sales support. ITL also secured the first right of refusal for future Memphasys reproductive technologies.

Commercial Strategy

Memphasys is complementing this partnership with a dual-track go-to-market approach. Alongside exclusive distribution agreements such as the ITL deal, the company is pursuing direct sales opportunities in selected regions to generate near-term revenues. Negotiations are at an advanced stage in New Zealand, Japan, and India, where volume-based agreements are expected to be finalised in the coming quarters. These are projected to deliver commercialisation revenues from FY2026.

This framework is designed to accelerate adoption of Felix™, seed demand in advance of regulatory approval, and diversify revenues geographically. The strategy also enables the company to establish early reference sites, integrate workflows more effectively, and position Felix™ for scale once CE Mark approval is obtained.

Next Steps

Immediate activities will include market preparation and clinician education programs across MENA in collaboration with ITL. Upon regulatory approval, Memphasys will supply Felix™ consoles and consumables under the agreement, providing clinics with access to its sperm preparation technology.